What does Oryzon Genomics, S.A.'s U.S. patent application cover?

The allowed claims cover combinations of iadademstat, or certain other LSD1 inhibitors, with gilteritinib, together with their use for treating myeloid cancers including AML. The application is U.S. patent application No. US 18/554,241.

Has Oryzon Genomics, S.A. already been granted the U.S. patent for the iadademstat and gilteritinib combination?

No completed U.S. patent grant was announced; the USPTO issued a Notice of Allowance for the application. The U.S. patent is expected to expire in 2042 once granted, excluding any potential patent term adjustment or patent term extension.

When is Oryzon Genomics, S.A.'s U.S. patent expected to expire?

Oryzon Genomics, S.A. said the U.S. patent is expected to expire in 2042 once granted. This excludes any potential patent term adjustment or patent term extension.

Has Oryzon Genomics, S.A. received related patent protection outside the United States?

Yes. Oryzon Genomics, S.A. said a corresponding patent had recently been granted in Taiwan, while additional patent applications were pending in other jurisdictions.

What did Oryzon Genomics, S.A.'s Chief IP Officer say about the U.S. Notice of Allowance?

Neus Virgili, Oryzon Genomics, S.A.'s Chief IP Officer, said the Notice of Allowance further strengthens the intellectual property protection around iadademstat and its use in combination with gilteritinib in AML. She also said the allowance reinforces the long-term protection of the iadademstat franchise alongside the company's broader portfolio of patents covering iadademstat combinations with other AML therapies.

How many oncology clinical trials are evaluating Oryzon Genomics, S.A.'s iadademstat?

Oryzon Genomics, S.A. said iadademstat was being evaluated in seven ongoing oncology clinical trials. These include the Phase Ib FRIDA study and the Phase Ib ALICE-2 study.

What is Oryzon Genomics, S.A.'s FRIDA study evaluating?

The Phase Ib FRIDA study is evaluating iadademstat in combination with gilteritinib in FLT3-mutated relapsed/refractory AML. Oryzon Genomics, S.A. reported a composite complete remission (CRc) rate of 67% at the dose level selected for expansion in a heavily pretreated population, together with a favourable safety profile.

What clinical results did Oryzon Genomics, S.A. report from the FRIDA study?

Oryzon Genomics, S.A. reported a 67% composite complete remission (CRc) rate at the dose level selected for expansion in a heavily pretreated population with relapsed/refractory FLT3-mutated AML, together with a favourable safety profile. The company compared this with contemporary real-world data for gilteritinib monotherapy, which reported a CR/CRi rate of 28% and median overall survival of 7.1 months in a broadly comparable population.

What is Oryzon Genomics, S.A.'s ALICE-2 study evaluating?

The Phase Ib ALICE-2 study is evaluating iadademstat in combination with venetoclax and azacitidine in first-line AML. Oryzon Genomics, S.A. reported a 100% overall response rate, an 89% CRc rate and a 78% complete remission rate.

When does Oryzon Genomics, S.A. expect to present additional data from the FRIDA and ALICE-2 studies?

Oryzon Genomics, S.A. said additional, more mature data from both studies were expected to be presented by year-end. The source does not provide a more specific date.

What other intellectual property does Oryzon Genomics, S.A. have for iadademstat combinations?

Oryzon Genomics, S.A. said it has patent protection covering combinations of iadademstat with venetoclax, azacitidine and other AML therapies. This includes granted patents in the United States and other major markets.

What does Oryzon Genomics, S.A. do and where does its stock trade?

Oryzon Genomics, S.A. describes itself as a clinical-stage biopharmaceutical company focused on epigenetics. The source gives its ISIN Code as ES0167733015 and its symbol as ORY; it does not identify a stock exchange in the provided content.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon reports U.S. Notice of Allowance for iadademstat-gilteritinib patent application

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon reports U.S. Notice of Allowance for iadademstat-gilteritinib patent application

Published Monday, 31 August 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Regulatory approval
Published: Monday, 31 August 2026
Source announcement: oryzon.com

Key figures
Measure	Figure
Composite complete remission (CRc) rate	67%
Overall response rate	100%
CRc rate	89%
Complete remission rate	78%

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced that the USPTO issued a Notice of Allowance for a patent application covering iadademstat combinations.

The application is US 18/554,241, titled “Combinations of LSD1 inhibitors for treating myeloid cancers”.
Allowed claims cover iadademstat, or certain other LSD1 inhibitors, with gilteritinib for treating myeloid cancers, including AML.
Once granted, the U.S. patent is expected to expire in 2042, excluding potential patent term adjustment or extension.
A corresponding patent has recently been granted in Taiwan; additional patent applications remain pending in other jurisdictions.
The announcement also describes granted U.S. and other-market patents covering iadademstat combinations with venetoclax, azacitidine and other AML therapies.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) said iadademstat is being evaluated in seven ongoing oncology clinical trials, including FRIDA and ALICE-2. Additional, more mature data from both studies are expected by year-end.

Investor FAQs

Oryzon Genomics, S.A. announced that the United States Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. patent application No. US 18/554,241, entitled “Combinations of LSD1 inhibitors for treating myeloid cancers”. The allowed claims cover combinations of iadademstat, or certain other LSD1 inhibitors, with gilteritinib and their use in treating myeloid cancers, including acute myeloid leukaemia (AML).

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON announces Notice of Allowance for U.S. patent application covering iadademstat combination with gilteritinib
Published: Monday, 31 August 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…